| TUHURA BIOSCIENCES INC. |
| USA |
| Gesundheit |
| US8989201038 / A3EWMJ |
| PL3 (Frankfurt) / HURA (NASDAQ) |
| FRA:PL3, ETR:PL3, PL3:GR, NASDAQ:HURA |
| - |
| https://tuhurabio.com/ |
|
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company focused on developing innovative therapeutics that aim to overcome both primary and acquired resistance to cancer immunotherapies. The company leverages its proprietar..
>Volltext.. |
| 90.83 Mio. EUR |
| 89.27 Mio. EUR |
| - |
| -21.92 Mio. EUR |
| -25.32 Mio. EUR |
| -0.56 EUR |
| 0.5 Mio. EUR |
| 2.33 Mio. EUR |
| -21.33 Mio. EUR |
| 0.31 |
| - |
| -132.57% |
| - |
| - |
| - |
| - |
| TUHURA |
| 02.04.26 |
|